Hillhurst Biopharmaceuticals, Inc. Clinical Trial Pipeline: 1 Active Trials, 5 Changes This Month

1

Active Trials

1

Recruiting

1

Disease Areas

5

Changes, 30 Days

What Changed in the Last 30 Days

Detected	Trial	Change
2026-08-07	NCT06144749 A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide…	Trial completed
2026-08-07	NCT06144749 A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide…	Phase changed: Phase 1/2 -> Phase 2
2026-08-07	NCT06144749 A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide…	Enrollment increased: 9 -> 13 participants
2026-08-07	NCT06144749 A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide…	date change Primary completion pushed: 2026-03-31 -> 2026-06-30
2026-08-07	NCT07005180 Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and…	Trial sites expanded: 1 -> 5 locations

Active Trials by Phase

Phase 2

1

Active Trials

NCT ID	Title	Condition	Status
Phase 2
NCT07005180	Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and…	Parkinson Disease	Recruiting

Disease Areas

Get alerts when Hillhurst Biopharmaceuticals, Inc.'s trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.